Compare Citius Pharmaceuticals Inc (CTXR) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.21 (market cap $4.35B). The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is far larger — about 319.4× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 3,211,044). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF for 41 Days on average.
| CTXR | SJNK | |
|---|---|---|
Market Cap | $13.62M | $4.35B |
Volume | 132,438 | 3,211,044 |
Sector | Health | Fixed Income |
52-Week High | $1.82 | $25.57 |
52-Week Low | $0.48 | $24.13 |
Typical Hold Time | 17 Days | 41 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
SJNK (SPDR Bloomberg Short Term High Yield Bond ETF) trades at $24.21, showing minimal daily movement with a 0.04% gain. Technical indicators signal bearish momentum with moving averages heavily favoring selling pressure, though oscillators remain neutral. The ETF continues its dividend distribution pattern with recent payments of $0.14-$0.15 per share. Institutional activity shows mixed sentiment with Cetera Investment Advisers maintaining a $17.83 million position while Balefire LLC significantly reduced its holdings by 74.7% in recent quarters.
The ETF faces headwinds from bearish technical signals despite attractive yield comparisons to Treasury bonds. Current price consolidation near $24 support levels suggests cautious investor sentiment. Dividend consistency provides income appeal, but institutional selling pressure and technical weakness indicate near-term challenges for price appreciation amid competitive fixed-income alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
